| dc.contributor.author | Jadhav, Hemant R. | |
| dc.date.accessioned | 2023-12-01T09:18:14Z | |
| dc.date.available | 2023-12-01T09:18:14Z | |
| dc.date.issued | 2023 | |
| dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374295/ | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13304 | |
| dc.description.abstract | Therapeutics comprising of nucleotide entities is very broad class, covers nucleotide analogs, oligonucleotides and nucleic acid-based based therapeutic. Nucleotide/nucleoside-based drugs are already very well explored, with clinically approved candidates as antiviral, anti-cancer, anti-bacterial and anti-rheumatoid etc (Garner, 2021). Oligonucleotide therapy is relative recent and promising, comprising of Antisense Oligonucleotides (ASOs), Small Interfering RNAs (siRNAs), Short Hairpin RNAs (shRNAs), Anti-MicroRNAs (anti-miRs). Oligonucleotides selectively bind to RNA or proteins, blocking their function or promoting degradation. Oligonucleotide therapy shows potential in treating genetic disorders, cancer, viral infections, and neurodegenerative conditions | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Frontiers | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Oligonucleotide therapeutics (OT) | en_US |
| dc.subject | Drugs | en_US |
| dc.subject | Oligonucleotide therapy | en_US |
| dc.subject | Antisense Oligonucleotides (ASOs) | en_US |
| dc.subject | Small Interfering RNAs (siRNAs) | en_US |
| dc.title | Recent trends and spotlight on nucleotide-based drugs: novel targets, their design, delivery, and clinical potential | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||